Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA

NDA FilingCAM2029Positive

AI Analysis

Summary

Camurus announced that the FDA has accepted for review the resubmission of its New Drug Application for CAM2029 (octreotide) for the treatment of acromegaly.

Outcome Details

NDA resubmission accepted for review

Importance:7/10

Sentiment:

0.70

FDANDAAcromegalyRegulatory

Related Companies

$CAMX

Read the original article

Published by Drugs.com New Drug Applications on July 17, 2026 2:07 AM

Read Original